Global Pricing Innovations (GPI)

Reimbursement status for approved drugs, competitors and standard of care, across the markets you work in. Run it on your own at no charge.

A dedicated Customer Success Manager and a 24 hour response on data queries. Run GPI alongside what you use today.

Cross-market comparison without harmonising several sources yourself first. Run GPI alongside what you use today, at no charge.

LFB on working with GPI. Run us alongside your current provider, on your own markets, with no charge for the evaluation period.

Pfizer on GPI cost of treatment data. See what it returns on your own markets, at no charge for the evaluation period.

A gene therapy is paid for once. The doubt about it can last much longer. The first EU Joint Clinical Assessment for a gene therapy has been published. It covered Onasemnogene abeparvovec intrathecal (Itvisma) for 5q spinal muscular atrophy. The Health Technology Developer argued the therapy was comparable to nusinersen and risdiplam on the basis of non-significant differences in indirect comparisons. The assessors rejected that framing, and picked apart the methodology on three further grounds. Why unresolved comparability hits harder for a single-administration therapy than a chronic one, what the assessors specifically said, and how the ruling reached national reimbursement in Ireland before the JCA was even published, all on the GPI website. https://lnkd.in/dpA5xwFH #HTA #JointClinicalAssessment #GeneTherapy #RareDisease #GPI